Anlotinib Not Yet Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03672136Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
NCT03728374Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma